OssDsign
OssDsign is a Sweden-based orthobiologics company that develops and sells OssDsign Catalyst, a nanosynthetic silicate-substituted bone graft for spinal fusion and orthopedic procedures, primarily to U.S. hospitals and surgeons through a direct sales force and IDN agreements.
- Company typePublic
- Founded2011
- HeadquartersUppsala, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What OssDsign does
OssDsign AB (publ) is a Sweden-based, Nasdaq First North–listed orthobiologics company that develops, manufactures, and commercializes the OssDsign Catalyst bone graft substitute — a nanosynthetic, silicate-substituted calcium phosphate designed to upregulate cellular BMP-2, drive dual-pathway (endochondral and intramembranous) healing, and undergo cell-mediated coupled remodeling. The company is the product of a 2011 Uppsala University / Karolinska University spinout, an orthopedic pivot enabled by the November 2020 acquisition of SIRAKOSS Ltd, and a January 2024 strategic restructuring that discontinued the legacy cranial implant business to make Catalyst the sole commercial focus.
The company's commercial product, OssDsign Catalyst, is sold in 1cc–10cc putty volumes for spinal fusion (including ACDF, posterior, deformity, posterolateral, and interbody applications across cervical, thoracic, and lumbar), as well as pelvic (sacroiliac, hip revision), extremity, and trauma indications. Catalyst became the first synthetic bone graft to receive FDA clearance for spinal interbody fusions based on bone graft data alone, with supporting clinical evidence including a 93% fusion rate in the TOP FUSION first-in-human study and 88.4% fusion in the real-world PROPEL registry's complex-patient cohort.
OssDsign generates revenue entirely through B2B hardware sales of Catalyst to hospitals, surgical centers, and surgeons, primarily in the United States through a direct sales force that the company intends to double by 2026, complemented by Integrated Delivery Network (IDN) agreements that provide network-wide access with pre-negotiated pricing. The company reported FY2025 revenue of SEK 180.2 million (~45% growth at constant FX) at a 96.3% gross margin, while remaining EBITDA-negative as it invests in U.S. commercial expansion, clinical programs, and production scaling — funded in part by directed share issues of SEK 150M (September 2023) and SEK 158M (June 2025).
OssDsign firmographics
Firmographics- Name
- OssDsign
- Legal name
- OssDsign AB (publ)
- Website
- https://ossdsign.com
- Company type
- Public
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- OssDsign is a Sweden-based orthobiologics company that develops and sells OssDsign Catalyst, a nanosynthetic silicate-substituted bone graft for spinal fusion and orthopedic procedures, primarily to U.S. hospitals and surgeons through a direct sales force and IDN agreements.
- Ownership category
- akta.pro rank
OssDsign industry classification
Industry- Product category
- Orthobiologics and Bone Graft Substitutes
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
- akta.pro secondary industries
- Spine Implants & Motion Preservation (Fusion/Disc/Interspinous) (HLAHAEAC), Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle) (HLAHAEAA), Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation) (HLAHAEAB)
Keywords
Where OssDsign is headquartered
LocationHeadquarters
- HQ city
- Uppsala
- HQ country
- Sweden
- HQ region
- Europe
Offices3 records
Markets served
OssDsign business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain
Revenue model
- OssDsign Catalyst Bone Graft Sales: Sale of nanosynthetic bone graft products to hospitals, surgical centers, and surgeons. Revenue generated from product sales in spinal fusion, extremity, pelvis, and trauma applications. The company has shown strong growth with 45% annual revenue growth and high gross margins of 96.3%.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
OssDsign product offering
Product offeringCore offering
OssDsign develops and commercializes OssDsign Catalyst, a nanosynthetic, silicate-substituted bone graft substitute cleared by the FDA for spinal interbody fusions and orthopedic applications. The product is sold in putty form (1cc, 2.5cc, 5cc, 10cc) to hospitals and surgeons, primarily in the U.S. market, for use in spinal fusion (cervical, thoracic, lumbar), sacroiliac fusion, extremities, and trauma indications.
Product overview
OssDsign is a developer and global provider of next generation orthobiologics products. The company operates as a pure play orthobiologics company following a strategic shift in September 2023, focusing solely on its OssDsign Catalyst platform. OssDsign Catalyst is a nanosynthetic, silicate-substituted bone graft substitute that supports the body's own healing capabilities. The product is indicated for use in multiple applications including spinal fusion procedures (cervical, thoracic, lumbar), pelvic procedures (sacroiliac fusion, hip revision), extremities (foot & ankle, hand & wrist), and trauma (fractures, non-unions). It was the first synthetic bone graft to receive clearance for use in spinal interbody fusions based on bone graft data alone.
Differentiator
Problem solved
Functional benefit
Brands
- OssDsign Catalyst: Nanosynthetic, silicate-substituted bone graft designed to upregulate cellular BMP-2, drive dual-pathway healing, and cell-mediated coupled remodeling for rapid, robust fusion in spine and other orthopedic applications
- PROPEL Spine Registry
- TOP FUSION
Products and services
- OssDsign Catalyst A nanosynthetic, silicate-substituted bone graft substitute designed to upregulate cellular BMP-2, drive dual-pathway healing (endochondral + intramembranous ossification), and enable cell-mediated coupled remodeling for rapid, robust fusion. Available in putty form in 1cc, 2.5cc, 5cc, and 10cc sizes. Indicated for spinal fusion (cervical, thoracic, lumbar, including ACDF, posterior fusion, deformity correction, posterolateral fusion, interbody fusion), sacroiliac fusion, hip revision, foot & ankle, hand & wrist, and trauma (fractures, non-unions). Sold to hospitals, surgical centers, and spine/orthopedic surgeons via direct sales force. First synthetic bone graft cleared by FDA for spinal interbody fusions based on bone graft data alone.
Quantifiable outcome
- 93% fusion rate within 12 months in complex multi-level spinal surgeries
- +5 more outcomes
Companies that use OssDsign
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles3 records
OssDsign technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
OssDsign partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Ernst & Young ABminorRe-elected as company auditor at 2026 AGM. Provides audit services per Swedish Companies Act requirements.
Scale indicators10 records
Recent moves9 records
Expansion highlights5 records
OssDsign competitors and assessment
Company assessmentBroad incumbents
- Medtronic: Largest spine and orthopedic device company with the Infuse Bone Graft (rhBMP-2) product, the dominant alternative to OssDsign Catalyst in spinal fusion. Directly comparable because it competes for the same spine surgeon customer, the same IDN formulary decision, and the same procedure indications.
- DePuy Synthes (Johnson & Johnson MedTech): Major spine and orthopedic franchise offering bone graft and biologic solutions alongside extensive hardware portfolios. Comparable as an incumbent competing for the same spine surgeon adoption and IDN contracts in spinal fusion.
- Stryker: Global orthopedics and spine incumbent with a broad portfolio including bone graft substitutes, demineralized bone matrix products, and biologics. Comparable as a competing orthobiologics and spine hardware supplier targeting the same hospital and IDN customers.
- Orthofix Medical: Spine and orthopedic device company with a dedicated biologics portfolio (including Trinity ELITE and FiberFuse) and trauma fixation. Comparable as a competing orthobiologics supplier and adjacent spine/trauma hardware player; Adam McCollister's prior experience at Orthofix reinforces the commercial comparability.
- NuVasive (legacy entity, now part of Globus Medical): Major spine surgery specialist with proprietary orthobiologics offerings (Osteocel, AttraX). Comparable as a spine-focused competitor in the same bone graft substitute category, with strong surgeon relationships in spinal fusion procedures.
Direct peers
- Globus Medical: Spine-focused pure-play with significant orthobiologics offerings following the NuVasive merger. Comparable as a direct competitor in spinal fusion procedures, including bone graft substitutes, targeting the same spine surgeons and hospitals.
- SeaSpine: Spine-focused pure-play acquired by Integra LifeSciences, with a portfolio including bone graft substitutes and orthobiologics (OsteoStrand, OsteoSurge). Comparable as a spinal fusion-focused orthobiologics competitor with a similar surgeon and IDN customer profile.
- Cerapedics: Commercial-stage orthobiologics company with i-FACTOR peptide-enhanced bone graft, the first PMA-approved bone graft for cervical spine. Comparable as a focused orthobiologics player competing in spinal fusion with a differentiated biologic/synthetic bone graft.
- BONESUPPORT: Pure-play orthobiologics company marketing CERAMENT, a synthetic injectable bone graft substitute. Highly comparable as a similarly sized European-headquartered pure-play orthobiologics competitor with synthetic bone graft technology for trauma, foot/ankle, and spine-adjacent indications.
- Xtant Medical: Pure-play orthobiologics company offering a portfolio of bone graft substitutes and fixation devices for spine and orthopedic surgery. Comparable as a similarly sized orthobiologics-focused public peer competing in the same hospital channel.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
OssDsign social profiles
Digital presenceOssDsign financial estimates
Financial estimateRevenue estimate
Valuation estimate
OssDsign leadership team
Management profileNumber of profiles
Profiles7 records
OssDsign funding detail
Funding detailFunding overview
Funding rounds5 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OssDsign M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OssDsign
What does OssDsign do?
OssDsign develops and commercializes OssDsign Catalyst, a nanosynthetic, silicate-substituted bone graft substitute cleared by the FDA for spinal interbody fusions and orthopedic applications. The product is sold in putty form (1cc, 2.5cc, 5cc, 10cc) to hospitals and surgeons, primarily in the U.S. market, for use in spinal fusion (cervical, thoracic, lumbar), sacroiliac fusion, extremities, and trauma indications.
Is OssDsign a public or private company?
OssDsign is a public company. It is classified as public and is currently operating.
When was OssDsign founded?
OssDsign was founded in 2011. It employs 11 to 50 people.
Where is OssDsign based?
OssDsign is headquartered in Uppsala, Sweden, in the Europe region.
How does OssDsign make money?
One revenue line is on record: ossDsign Catalyst Bone Graft Sales.
Who are OssDsign's main competitors?
Broad incumbents on record are Medtronic, DePuy Synthes (Johnson & Johnson MedTech), Stryker, Orthofix Medical and NuVasive (legacy entity, now part of Globus Medical). Direct peers are Globus Medical, SeaSpine, Cerapedics, BONESUPPORT and Xtant Medical.
Does OssDsign have an API?
No public API is recorded for OssDsign.
What industry is OssDsign in?
OssDsign's product category is Orthobiologics and Bone Graft Substitutes. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAHAEAC, Spine Implants & Motion Preservation (Fusion/Disc/Interspinous). Its NAICS code is 339113 and its SIC code is 3842.